Clinical trial · Observational
Evaluation of Sexual Quality of Life for Breast Cancer
Evaluation of Sexual Quality of Life in Women Less Than 51 Years Old, During Adjuvant Hormonal Therapy for Breast Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Breast cancer is the most common cancer in women worldwide. Hormonal therapy is one of the major treatments for hormone receptor positive breast tumors. It is prescribed to 70% of breast cancer patients. Hormonal therapy can be responsible for sexual dysfunction induced by hormonal changes. Extended adjuvant hormonal therapy over 5 years increases these adverse effects. According to the third "Plan Cancer" (2014-2019), sexual dysfunction prevention and screening must be systematic as an integral part of supportive care. Nevertheless, sexual quality of life remains too rarely considered. In this study, the investigator propose to evaluate sexual quality of life of women less than 51 years old during the adjuvant endocrine therapy for localized breast cancer. The investigator also intend to collect the supportive measures or interventions used by women to overcome sexual dysfunction. Finally, this study aims to evaluate the need for sexual trouble specific management and acceptability of different methods. This project is a hot topic as the interest for oncosexuality is growing, and the need for specific management is increasing with still insufficient access to specific care.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Quality of Life | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Quality of life | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- adjuvant hormonal therapy for breast cancer
- description
- women less than 51 years old, during adjuvant hormonal therapy for breast cancer
- interventionNames
- Other: Quality of life
Primary outcomes (1)
- measure
- Sexual quality of life: EORTC SHQ-C22 questionnaire
- timeFrame
- At the inclusion, at one time
- description
- Sexual quality of life assessed by the EORTC SHQ-C22 questionnaire
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 51 Years
Show eligibility criteria text
Inclusion Criteria: * Female age ≥ 18 years old and less than 51 years old. * Patient with non-metastatic early breast cancer, * Patient undergoing adjuvant hormonal therapy for at least 2 years, * Patient who has been treated by surgery, with or without chemotherapy and/or radiotherapy. * Patient being currently sexually active. * Patient who agreed, after receiving information, to participate to the study. Exclusion Criteria: * Patient who refused to participate to this study or is unable to fulfill a questionnaire, * Patient not affiliated to the French social security system, * Subject under tutelage, curatorship or safeguard of justice, * Patient in an emergency situation, * Patient whose regular monitoring is impossible for psychological, family, social or geographical reasons, * Pregnant and / or breastfeeding woman.
References
Publications (2)
- BACKGROUNDPouget JP, Lozza C, Deshayes E, Boudousq V, Navarro-Teulon I. Introduction to radiobiology of targeted radionuclide therapy. Front Med (Lausanne). 2015 Mar 17;2:12. doi: 10.3389/fmed.2015.00012. eCollection 2015. PMID 25853132
- BACKGROUNDKumar C, Shetake N, Desai S, Kumar A, Samuel G, Pandey BN. Relevance of radiobiological concepts in radionuclide therapy of cancer. Int J Radiat Biol. 2016;92(4):173-86. doi: 10.3109/09553002.2016.1144944. Epub 2016 Feb 26. PMID 26917443